Actively Recruiting
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Led by AstraZeneca · Updated on 2026-05-14
163
Participants Needed
44
Research Sites
332 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
CONDITIONS
Official Title
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years or older at the time of signing the informed consent form
- Body weight greater than 35 kg
- No prior treatment for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
- Measurable target disease based on RECIST 1.1 assessed by the investigator
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 12 weeks
- Adequate organ and bone marrow function
- Confirmed Claudin18.2 status from tumor sample collected within the past 24 months or from a fresh biopsy when Substudy 3 or 4 is recruiting
You will not qualify if you...
- HER2-positive or indeterminate gastric or GEJ carcinoma
- Untreated or progressing brain metastases, leptomeningeal disease, or spinal cord compression
- Uncontrolled ascites
- Active infections including tuberculosis, HIV, or hepatitis B or C
- Uncontrolled intercurrent illnesses
- Active or prior autoimmune or inflammatory disorders needing systemic steroid or immunosuppressive treatment
- History of another primary cancer
- Previous treatment with immune-oncology agents
- Previous treatment with Claudin18.2 targeted therapy or MMAE exposure when Substudy 3 or 4 is open for recruitment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 44 locations
1
Research Site
Los Angeles, California, United States, 90017
Actively Recruiting
2
Research Site
Los Angeles, California, United States, 90095
Withdrawn
3
Research Site
Baton Rouge, Louisiana, United States, 70817
Actively Recruiting
4
Research Site
Grand Rapids, Michigan, United States, 49503
Actively Recruiting
5
Research Site
New Hyde Park, New York, United States, 11042
Withdrawn
6
Research Site
New York, New York, United States, 10028
Withdrawn
7
Research Site
New York, New York, United States, 10065
Actively Recruiting
8
Research Site
New York, New York, United States, 11210
Withdrawn
9
Research Site
Shirley, New York, United States, 11967
Withdrawn
10
Research Site
The Bronx, New York, United States, 10469
Withdrawn
11
Research Site
Pittsburgh, Pennsylvania, United States, 15212
Withdrawn
12
Research Site
Beijing, China, 100142
Actively Recruiting
13
Research Site
Hangzhou, China, 310003
Actively Recruiting
14
Research Site
Hangzhou, China, 310020
Actively Recruiting
15
Research Site
Harbin, China, 150081
Actively Recruiting
16
Research Site
Hefei, China, 230031
Actively Recruiting
17
Research Site
Kunming, China, 650118
Completed
18
Research Site
Wuhan, China, 430079
Actively Recruiting
19
Research Site
Yinchuan, China, 750004
Actively Recruiting
20
Research Site
Zhengzhou, China, 450052
Actively Recruiting
21
Research Site
Chūōku, Japan, 104-0045
Actively Recruiting
22
Research Site
Kashiwa, Japan, 227-8577
Actively Recruiting
23
Research Site
Sunto-gun, Japan, 411-8777
Actively Recruiting
24
Research Site
Seoul, South Korea, 03080
Actively Recruiting
25
Research Site
Seoul, South Korea, 03722
Actively Recruiting
26
Research Site
Seoul, South Korea, 05505
Actively Recruiting
27
Research Site
Seoul, South Korea, 06351
Actively Recruiting
28
Research Site
Barcelona, Spain, 08035
Actively Recruiting
29
Research Site
Elche(Alicante), Spain, 03202
Actively Recruiting
30
Research Site
L'Hospitalet de Llobregat, Spain, 08908
Actively Recruiting
31
Research Site
Madrid, Spain, 28007
Actively Recruiting
32
Research Site
Madrid, Spain, 28040
Actively Recruiting
33
Research Site
Santander, Spain, 39008
Actively Recruiting
34
Research Site
Hsinchu, Taiwan, 300
Actively Recruiting
35
Research Site
Kaohsiung City, Taiwan, 80756
Actively Recruiting
36
Research Site
Taichung, Taiwan, 404
Actively Recruiting
37
Research Site
Tainan, Taiwan, 70403
Actively Recruiting
38
Research Site
Taipei, Taiwan, 10002
Actively Recruiting
39
Research Site
Taipei, Taiwan, 11259
Actively Recruiting
40
Research Site
Taoyuan, Taiwan, 333
Actively Recruiting
41
Research Site
Edinburgh, United Kingdom, EH4 2XU
Withdrawn
42
Research Site
Leeds, United Kingdom, LS9 7TF
Actively Recruiting
43
Research Site
London, United Kingdom, EC1M 6BQ
Actively Recruiting
44
Research Site
Oxford, United Kingdom, OX3 7LE
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here